Abbott Laboratories (NYSE: ABT) on Thursday introduced monetary outcomes for the second quarter of fiscal 2025, reporting a rise in gross sales and adjusted revenue. The outcomes additionally exceeded Wall Road’s estimates.
Complete reported gross sales elevated 7.4% year-over-year to $11.14 billion within the second quarter. Natural gross sales grew 6.9%, or 7.5% excluding COVID-19 testing-related gross sales.
Adjusted earnings rose to $1.26 per share in Q2 from $1.14 per share within the year-ago quarter and got here in barely above analysts’ expectations. Unadjusted revenue rose sharply to $1.78 billion or $1.01 per share within the second quarter from $1.30 billion or $0.74 per share in Q2 2024.
“Midway via the yr, we delivered excessive single-digit natural gross sales progress, double-digit EPS progress, considerably expanded our margin profiles, and continued to advance key applications via our new product pipeline,” stated Robert Ford, chief govt officer of Abbott.
